« Back

Sarepta Therapeutics to Present at Leerink Partners Rare Disease Roundtable

09/24/14 5:26 PM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 24, 2014-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to participate in a fireside chat at the Leerink Partners Rare Disease Roundtable in New York on Wednesday, October 1, 2014, at 8:00 a.m. ET.

The discussion will be webcast live on the investor relations section of the Sarepta Therapeutics website at www.sarepta.com and will be archived under the events and presentations section following the presentation for 90 days.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sarepta.com.

Source: Sarepta Therapeutics, Inc.

Sarepta Investor Contact:
Stephanie Ascher, 212-362-1200
stephanie@sternir.com
or
Sarepta Media Contact:
Tony Plohoros, 908-591-2839
tplohoros@6degreesPR.com

 

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.